↓ Skip to main content

Dove Medical Press

Article Metrics

New advances in the treatment of generalized lipodystrophy: role of metreleptin

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
5 tweeters
googleplus
1 Google+ user
video
1 video uploader

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
50 Mendeley
Title
New advances in the treatment of generalized lipodystrophy: role of metreleptin
Published in
Therapeutics and Clinical Risk Management, September 2015
DOI 10.2147/tcrm.s66521
Pubmed ID
Authors

Gilberto Paz-Filho, Alexander Rodriguez, Claudio Mastronardi

Abstract

Recombinant methionyl human leptin or metreleptin is a synthetic leptin analog that has been trialed in patients with leptin-deficient conditions, such as leptin deficiency due to mutations in the leptin gene, hypothalamic amenorrhea, and lipodystrophy syndromes. These syndromes are characterized by partial or complete absence of adipose tissue and hormones derived from adipose tissue, most importantly leptin. Patients deficient in leptin exhibit a number of severe metabolic abnormalities such as hyperglycemia, hypertriglyceridemia, and hepatic steatosis, which can progress to diabetes mellitus, acute pancreatitis, and hepatic cirrhosis, respectively. For the management of these abnormalities, multiple therapies are usually required, and advanced stages may be progressively difficult to treat. Following many successful trials, the US Food and Drug Administration approved metreleptin for the treatment of non-HIV-related forms of generalized lipodystrophy. Leptin replacement therapy with metreleptin has, in many cases, reversed these metabolic complications, with improvements in glucose-insulin-lipid homeostasis, and regression of fatty liver disease. Besides being effective, a daily subcutaneous administration of metreleptin is generally safe, but the causal association between metreleptin and immune complications (such as lymphoma) is still unclear. Moreover, further investigation is needed to elucidate mechanisms by which metreleptin leads to the development of anti-leptin antibodies. Herein, we review clinical aspects of generalized lipodystrophy and the pharmacological profile of metreleptin. Further, we examine studies that assessed the safety and efficacy of metreleptin, and outline some clinical perspectives on the drug.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 49 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 28%
Student > Bachelor 10 20%
Student > Master 6 12%
Student > Postgraduate 6 12%
Student > Ph. D. Student 4 8%
Other 5 10%
Unknown 5 10%
Readers by discipline Count As %
Medicine and Dentistry 11 22%
Biochemistry, Genetics and Molecular Biology 6 12%
Sports and Recreations 6 12%
Agricultural and Biological Sciences 4 8%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Other 12 24%
Unknown 8 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 March 2019.
All research outputs
#3,726,014
of 14,568,591 outputs
Outputs from Therapeutics and Clinical Risk Management
#177
of 1,016 outputs
Outputs of similar age
#50,296
of 203,072 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#9
of 61 outputs
Altmetric has tracked 14,568,591 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,016 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 203,072 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.